Skip to main content
Top
Published in: European Radiology 10/2020

01-10-2020 | Fibromatosis | Magnetic Resonance

The value of the black fiber sign on T1-weighted images for predicting stability of desmoid fibromatosis managed conservatively

Authors: Yasutaka Murahashi, Makoto Emori, Junya Shimizu, Ken Anzai, Takaaki Tanaka, Norifumi Naka, Hiroyuki Tsuchie, Hiroyuki Nagasawa, Naohisa Miyakoshi, Yoichi Shimada, Toshihiko Yamashita

Published in: European Radiology | Issue 10/2020

Login to get access

Abstract

Objectives

It is challenging to know at the first which patients with desmoid fibromatosis (DF) are better suited to conservative or aggressive treatment. To investigate whether the low signal intensity bundles on T1- or T2-weighted images (WI), termed the “black fiber sign (BFS),” can predict non-progressive behavior in the conservative approach.

Methods

This retrospective study included 59 patients with primary DF managed with wait-and-see approach from 2005 to 2018 and serial MR images were analyzed. Three observers blinded to the patient information verified the presence or absence of BFS on baseline T1 or T2WI. The likelihood of progression-free survival (PFS) after ascertaining the presence or absence of the BFS was estimated using the Kaplan–Meier method and analyzed with the log-rank test.

Results

PFS was significantly higher in cases with BFS than without BFS on T1WI (p < 0.01), but there was no significant difference in PFS between cases with and without BFS on T2WI. Multivariable Cox proportional hazards analysis revealed that the absence of BFS on T1WI was a high-risk factor for progression (hazard ratio, 14.9; p < 0.01). Drastic tumor regression was apparent with significantly increased low-signal area in cases with BFS on T1WI. Intra- and interobserver reliabilities of BFS on T1WI were in almost-perfect agreement (κ > 0.8).

Conclusion

Our retrospective observational data support that presence of BFS in baseline MRI may be a predictor for progression-free survival of DF. BFS on T1WI is easily identifiable and can be utilized clinically in patients with DF.

Key Points

• We proposed a new imaging marker for prediction of desmoid fibromatosis progression.
• The absence of black fiber sign predicted a high risk of disease progression.
Literature
1.
go back to reference Smith K, Desai J, Lazarakis S, Gyorki D (2018) Systematic review of clinical outcomes following various treatment options for patients with extraabdominal desmoid tumors. Ann Surg Oncol 25:1544–1554CrossRef Smith K, Desai J, Lazarakis S, Gyorki D (2018) Systematic review of clinical outcomes following various treatment options for patients with extraabdominal desmoid tumors. Ann Surg Oncol 25:1544–1554CrossRef
2.
go back to reference Kriz J, Eich HT, Haverkamp U et al (2014) Radiotherapy is effective for desmoid tumors (aggressive fibromatosis) - long-term results of a German multicenter study. Oncol Res Treat 37:255–260CrossRef Kriz J, Eich HT, Haverkamp U et al (2014) Radiotherapy is effective for desmoid tumors (aggressive fibromatosis) - long-term results of a German multicenter study. Oncol Res Treat 37:255–260CrossRef
3.
go back to reference Bonvalot S, Desai A, Coppola S et al (2012) The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol 23:x158–x166CrossRef Bonvalot S, Desai A, Coppola S et al (2012) The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol 23:x158–x166CrossRef
4.
go back to reference Gronchi A, Colombo C, Le Péchoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25:578–583CrossRef Gronchi A, Colombo C, Le Péchoux C et al (2014) Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol 25:578–583CrossRef
5.
go back to reference Fiore M, Rimareix F, Mariani L et al (2009) Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 16:2587–2593CrossRef Fiore M, Rimareix F, Mariani L et al (2009) Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 16:2587–2593CrossRef
6.
go back to reference Castellazzi G, Vanel D, Le Cesne A et al (2009) Can the MRI signal of aggressive fibromatosis be used to predict its behavior? Eur J Radiol 69:222–229CrossRef Castellazzi G, Vanel D, Le Cesne A et al (2009) Can the MRI signal of aggressive fibromatosis be used to predict its behavior? Eur J Radiol 69:222–229CrossRef
7.
go back to reference Francastel C, Schübeler D, Martin DI, Groudine M (2000) Nuclear compartmentalization and gene activity. Nat Rev Mol Cell Biol 1:137–143CrossRef Francastel C, Schübeler D, Martin DI, Groudine M (2000) Nuclear compartmentalization and gene activity. Nat Rev Mol Cell Biol 1:137–143CrossRef
8.
go back to reference Skubitz KM (2017) Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc 92:947–964CrossRef Skubitz KM (2017) Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc 92:947–964CrossRef
9.
go back to reference Rhim JH, Kim JH, Moon KC et al (2013) Desmoid-type fibromatosis in the head and neck: CT and MR imaging characteristics. Neuroradiology 55:351–359CrossRef Rhim JH, Kim JH, Moon KC et al (2013) Desmoid-type fibromatosis in the head and neck: CT and MR imaging characteristics. Neuroradiology 55:351–359CrossRef
10.
go back to reference Gounder MM, Lefkowitz RA, Keohan ML et al (2011) Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17:4082–4090CrossRef Gounder MM, Lefkowitz RA, Keohan ML et al (2011) Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17:4082–4090CrossRef
11.
go back to reference Martin-Liberal J, Benson C, McCarty H, Thway K, Messiou C, Judson I (2013) Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res 3:13CrossRef Martin-Liberal J, Benson C, McCarty H, Thway K, Messiou C, Judson I (2013) Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res 3:13CrossRef
12.
go back to reference Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447–456CrossRef Stacchiotti S, Collini P, Messina A et al (2009) High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447–456CrossRef
13.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef
14.
go back to reference Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef
15.
go back to reference Gondim Teixeira PA, Biouichi H, Abou Arab W et al (2020) Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis. Eur Radiol 30:895–902CrossRef Gondim Teixeira PA, Biouichi H, Abou Arab W et al (2020) Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis. Eur Radiol 30:895–902CrossRef
16.
go back to reference Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRef Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRef
17.
go back to reference Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating. Springer, Berlin Heidelberg, New YorkCrossRef Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating. Springer, Berlin Heidelberg, New YorkCrossRef
18.
go back to reference van Broekhoven DL, Verhoef C, Elias SG et al (2013) Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg 100:1214–1219CrossRef van Broekhoven DL, Verhoef C, Elias SG et al (2013) Local recurrence after surgery for primary extra-abdominal desmoid-type fibromatosis. Br J Surg 100:1214–1219CrossRef
19.
go back to reference Crago AM, Denton B, Salas S et al (2013) A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg 258:347–353CrossRef Crago AM, Denton B, Salas S et al (2013) A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg 258:347–353CrossRef
20.
go back to reference Cates JM, Stricker TP (2014) Surgical resection margins in desmoid-type fibromatosis: a critical reassessment. Am J Surg Pathol 38:1707–1714CrossRef Cates JM, Stricker TP (2014) Surgical resection margins in desmoid-type fibromatosis: a critical reassessment. Am J Surg Pathol 38:1707–1714CrossRef
21.
go back to reference Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29:3553–3558CrossRef Salas S, Dufresne A, Bui B et al (2011) Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 29:3553–3558CrossRef
22.
go back to reference Prodinger PM, Rechl H, Keller M et al (2013) Surgical resection and radiation therapy of desmoid tumours of the extremities: results of a supra-regional tumour centre. Int Orthop 37:1987–1993CrossRef Prodinger PM, Rechl H, Keller M et al (2013) Surgical resection and radiation therapy of desmoid tumours of the extremities: results of a supra-regional tumour centre. Int Orthop 37:1987–1993CrossRef
23.
go back to reference Gondim Teixeira PA, Chanson A, Verhaeghe JL et al (2019) Correlation between tumor growth and hormonal therapy with MR signal characteristics of desmoid-type fibromatosis: a preliminary study. Diagn Interv Imaging 100:47–55CrossRef Gondim Teixeira PA, Chanson A, Verhaeghe JL et al (2019) Correlation between tumor growth and hormonal therapy with MR signal characteristics of desmoid-type fibromatosis: a preliminary study. Diagn Interv Imaging 100:47–55CrossRef
24.
go back to reference Vandevenne JE, De Schepper AM, De Beuckeleer L et al (1997) New concepts in understanding evolution of desmoid tumors: MR imaging of 30 lesions. Eur Radiol 7:1013–1019CrossRef Vandevenne JE, De Schepper AM, De Beuckeleer L et al (1997) New concepts in understanding evolution of desmoid tumors: MR imaging of 30 lesions. Eur Radiol 7:1013–1019CrossRef
25.
go back to reference Braschi-Amirfarzan M, Keraliya AR, Krajewski KM et al (2016) Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics 36:767–782CrossRef Braschi-Amirfarzan M, Keraliya AR, Krajewski KM et al (2016) Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics 36:767–782CrossRef
27.
go back to reference Misemer BS, Skubitz AP, Carlos Manivel J et al (2014) Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity. Cancer Med 3:81–90CrossRef Misemer BS, Skubitz AP, Carlos Manivel J et al (2014) Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity. Cancer Med 3:81–90CrossRef
28.
go back to reference Sheth PJ, Del Moral S, Wilky BA et al (2016) Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiol 45:1365–1373CrossRef Sheth PJ, Del Moral S, Wilky BA et al (2016) Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiol 45:1365–1373CrossRef
Metadata
Title
The value of the black fiber sign on T1-weighted images for predicting stability of desmoid fibromatosis managed conservatively
Authors
Yasutaka Murahashi
Makoto Emori
Junya Shimizu
Ken Anzai
Takaaki Tanaka
Norifumi Naka
Hiroyuki Tsuchie
Hiroyuki Nagasawa
Naohisa Miyakoshi
Yoichi Shimada
Toshihiko Yamashita
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Keyword
Fibromatosis
Published in
European Radiology / Issue 10/2020
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-06953-z

Other articles of this Issue 10/2020

European Radiology 10/2020 Go to the issue